Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $62.17

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $62.17.

CLDX has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, July 30th. Wolfe Research initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, July 30th. Finally, Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price on the stock.

Insider Transactions at Celldex Therapeutics

In other news, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the sale, the vice president now owns 9,074 shares of the company’s stock, valued at approximately $305,249.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Samuel Bates Martin sold 17,172 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $35.42, for a total transaction of $608,232.24. Following the sale, the chief financial officer now owns 28,125 shares of the company’s stock, valued at $996,187.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Elizabeth Crowley sold 38,597 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the transaction, the vice president now owns 9,074 shares of the company’s stock, valued at approximately $305,249.36. The disclosure for this sale can be found here. Insiders have sold a total of 266,332 shares of company stock worth $9,155,821 in the last ninety days. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets grew its stake in shares of Celldex Therapeutics by 48.9% during the fourth quarter. BNP Paribas Financial Markets now owns 136,601 shares of the biopharmaceutical company’s stock worth $5,418,000 after purchasing an additional 44,878 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Celldex Therapeutics by 16.3% during the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock worth $120,817,000 after purchasing an additional 427,827 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Celldex Therapeutics by 105.3% during the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock worth $109,308,000 after purchasing an additional 1,413,722 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Celldex Therapeutics by 13.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after acquiring an additional 47,844 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in Celldex Therapeutics by 166.7% in the fourth quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after acquiring an additional 250,000 shares in the last quarter.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $33.51 on Wednesday. The business has a fifty day moving average of $36.65 and a 200 day moving average of $39.03. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -11.76 and a beta of 1.58. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, equities research analysts expect that Celldex Therapeutics will post -2.39 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.